Acutaas Chemicals Ltd. share price
NSE: ACUTAAS · Healthcare
₹3,947.30 -2.27%
Closing price data, updated 17 Nov 2026. 52-week range: -4.4% from high, +151.4% above low.
Price₹3,947.30
Market cap₹32,317 Cr
P/E73.6
P/B17.40
ROE24.1%
ROCE27.7%
Debt / equity0.02
Dividend yield0.00%
EPS₹53.64
Book value₹226.87
Operating margin33.5%
Dipscan score55 / 100
Share: WhatsAppX / TwitterTelegram
Acutaas Chemicals Ltd. shareholding pattern
As of Sep 2026: Promoters 32.66%, FIIs 22.62%, DIIs 19.40%, Government 0.01%, Public 21.15%, Others 4.16%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 32.66% | 32.66% | 32.66% | 32.66% | 32.66% | 32.66% |
| FIIs | 22.62% | 21.61% | 19.48% | 16.67% | 16.85% | 16.94% |
| DIIs | 19.40% | 19.56% | 19.60% | 21.70% | 22.59% | 22.38% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 21.15% | 21.72% | 23.21% | 23.53% | 22.79% | 23.27% |
| Others | 4.16% | 4.44% | 5.03% | 5.43% | 5.10% | 4.74% |
| No. of Shareholders | 147,026 | 125,569 | 112,939 | 110,363 | 108,664 | 119,890 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -2.27% | +4.24% | +24.89% | +26.90% | +44.76% | +124.80% |
Growth
| Sales growth, 3 years | +29.4% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +62.3% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | +73.3% |
Strengths and weaknesses
Strengths
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 45.8% CAGR over last 5 years
Weaknesses
- Stock is trading at 17.4 times its book value
- Promoter holding has decreased over last 3 years: -6.27%
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Acutaas Chemicals Ltd.?
Acutaas Chemicals Ltd. (ACUTAAS) last closed at ₹3,947.30 (-2.27% on the day).
What is the market cap of Acutaas Chemicals Ltd.?
About ₹32,317 Cr.
What is the P/E ratio of Acutaas Chemicals Ltd.?
The price-to-earnings ratio is 73.6, and return on equity is 24.1%.
Figures are calculated from company results and exchange prices and are for information only.